Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.48 |
| ▸ | DAO | P14920 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 3/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | CDC7 | O00311 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.37 |
| ▸ | HTR2B | P41595 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | CDK4 | P11802 | 1/20 | 0.36 |
| ▸ | CCND1 | P24385 | 1/20 | 0.36 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL113790 | 0.83 | MTNR1A (0.51) | MTNR1ADAOPARP1P2RX7HTR2C | |
| SCHEMBL30159029 | 0.81 | MTNR1A (0.50) | MTNR1ADAOPARP1P2RX7HTR2C | |
| SCHEMBL28027047 | 0.80 | MTNR1A (0.51) | MTNR1ADAOPARP1P2RX7HTR2C | |
| SCHEMBL3641041 | 0.80 | MTNR1A (0.46) | MTNR1ADAOPARP1P2RX7HTR2C | |
| SCHEMBL8827650 | 0.77 | MTNR1A (0.56) | MTNR1ADAOPARP1P2RX7HTR2C | |
| SCHEMBL17675693 | 0.77 | MTNR1A (0.46) | MTNR1ADAOPARP1P2RX7HTR2C | |
| SCHEMBL2543931 | 0.77 | MTNR1A (0.55) | MTNR1ADAOPARP1P2RX7HTR2C | |
| SCHEMBL16195505 | 0.77 | MTNR1A (0.55) | MTNR1ADAOPARP1P2RX7HTR2C | |
| SCHEMBL3643408 | 0.76 | DAO (0.43) | MTNR1ADAOPARP1P2RX7HTR2C | |
| SCHEMBL114693 | 0.75 | MTNR1A (0.57) | MTNR1ADAOPARP1P2RX7CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10287220-B2 | Fluorination method | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2019-05-14 | — | — | US | claimed |
| JP-4574167-B2 | — | — | 2010-11-04 | — | — | JP | claimed |
| US-7501505-B2 | Activators for oligonucleotide synthesis | AVECIA BIOTECHNOLOGY, INC. (US) | 2009-03-10 | — | — | US | claimed |
| CN-100430411-C | Activators for oligonucleotide synthesis | AVECIA LTD (US) | 2008-11-05 | — | — | CN | claimed |
| US-20060041114-A1 | Activators for oligonucleotide synthesis | NITTO DENKO AVECIA, INC. | 2006-02-23 | — | — | US | claimed |
| EP-1404696-B1 | ACTIVATORS FOR OLIGONUCLEOTIDE SYNTHESIS | AVECIA BIOTECHNOLOGY INC (US) | 2006-02-08 | — | — | EP | claimed |
| CN-1549820-A | Activators for oligonucleotide synthesis | ƽ | 2004-11-24 | — | — | CN | claimed |
| EP-1404696-A1 | ACTIVATORS FOR OLIGONUCLEOTIDE SYNTHESIS | Avecia Biotechnology, Inc. (US) | 2004-04-07 | — | — | EP | claimed |
| WO-2003004512-A1 | ACTIVATORS FOR OLIGONUCLEOTIDE SYNTHESIS | AVECIA BIOTECHNOLOGY INC. (US) | 2003-01-16 | — | — | WO | claimed |
| EP-2379549-B1 | 7-AZAINDIRUBINS, 7'-AZAINDIRUBINS, 7-7'-DIAZAINDIRUBIN AND THE CORRESPONDING 3'-OXIME ETHER DERIVATES: PRODUCTION THEREOF, THEIR PRODUCTION AND USE AS A MEDICAMENT | EISENBRAND GERHARD (DE) | 2016-09-21 | — | — | EP | disclosed |
| EP-1501851-B1 | PROCESS FOR PREPARING OLIGONUCLEOTIDES | NITTO DENKO AVECIA INC (US) | 2013-02-13 | — | — | EP | disclosed |
| US-8093397-B2 | Activators for oligonucleotide synthesis | AVECIA BIOTECHNOLOGY, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| EP-2379549-A1 | 7-AZAINDIRUBINS, 7'AZAINDIRUBINS, 7,7'-DIAZAINDIRUBINS AND THE CORRESPONDING 3'-OXIME ETHER DERIVATIVES THEREOF, THEIR PRODUCTION AND USE AS A MEDICAMENT | Eisenbrand, Gerhard (DE) | 2011-10-26 | — | — | EP | disclosed |
| EP-1575975-B1 | PROCESS FOR THE PREPARATION OF OLIGONUCLEOTIDES | AVECIA BIOTECHNOLOGY INC (US) | 2010-10-27 | — | — | EP | disclosed |
| WO-2004055036-A1 | PROCESS FOR THE PREPARATION OF OLIGONUCLEOTIDES | AVECIA LIMITED (GB) | 2004-07-01 | — | — | WO | disclosed |
| WO-2004035599-A1 | PHOSPHITYLATION PROCESS | AVECIA BIOTECHNOLOGY INC. (US) | 2004-04-29 | — | — | WO | disclosed |
| EP-1404696-A1 | ACTIVATORS FOR OLIGONUCLEOTIDE SYNTHESIS | Avecia Biotechnology, Inc. (US) | 2004-04-07 | — | — | EP | disclosed |
| WO-2003091267-A1 | PROCESS FOR PREPARING OLIGONUCLEOTIDES | AVECIA LIMITED (GB) | 2003-11-06 | — | — | WO | disclosed |
| WO-2003045969-A1 | COUPLING REAGENT FOR H-PHOSPHONATE CHEMISTRY | AVECIA BIOTECHNOLOGY INC. (US) | 2003-06-05 | — | — | WO | disclosed |
| WO-2003004512-A1 | ACTIVATORS FOR OLIGONUCLEOTIDE SYNTHESIS | AVECIA BIOTECHNOLOGY INC. (US) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10287220-B2 | Fluorination method | F13B, PPARG, PGC | MTNR1A 2789/4885DAO 1891/4885PARP1 1445/4885 |
| US-20060041114-A1 | Activators for oligonucleotide synthesis | MED12, RBM12, RPS12 | MTNR1A 290/4885DAO 818/4885PARP1 2624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.